OmniSeq Funding & Profile | Venture Capital Tracker

Overview

OmniSeq was a CAP/CLIA molecular diagnostic laboratory founded in 2015 in Buffalo, NY as a commercial spinout from Roswell Park Comprehensive Cancer Center's Center of Personalized Medicine. The company developed genomic and immune profiling assays for solid tumors, including the OmniSeq INSIGHT next-generation sequencing platform used to inform precision oncology treatment and clinical trial matching. After a multi-year distribution partnership with Labcorp, Labcorp announced on July 29, 2021 that it was acquiring OmniSeq to expand its oncology portfolio. OmniSeq's tests and services were integrated into Labcorp Oncology; the independent startup is no longer operating as a standalone company.

Why OmniSeq is interesting

Buffalo precision-oncology lab spun from Roswell Park in 2015 and acquired by Labcorp in July 2021 — a rare Upstate molecular diagnostics exit into a national lab platform.

Product & use cases

Clinical laboratory genomic and immune profiling for solid tumors (NGS and related assays), later offered through Labcorp Oncology after acquisition.

Oncologists ordering comprehensive solid tumor genomic/immune profiles
Biopharma biomarker and trial stratification services
Precision oncology treatment and trial matching

Key facts

Founded 2015 — Roswell Park Center of Personalized Medicine commercial spinout, Buffalo, NY
CAP-accredited, CLIA-licensed molecular diagnostic lab for solid tumor genomic/immune profiling
Jun 2021: Labcorp and OmniSeq launched OmniSeq INSIGHT NGS platform (pre-close partnership product)
Acquired by Labcorp (Jul 29, 2021) — oncology portfolio expansion
Standalone website retired; coverage is historical exit profile

Fundraising history

Acquisition

2021-07

Labcorp (lead)

Source: https://oncology.labcorp.com/cancer-care-team/news-events/labcorp-expands-oncology-portfolio-omniseqr-acquisition

Competitive landscape

Edge: Roswell Park–origin molecular lab with combined genomic and immune profiling — strategic enough for Labcorp to acquire after years of exclusive distribution.

Precision oncology diagnostics consolidated toward large lab and pharma-aligned platforms. OmniSeq's path — Roswell spinout, Labcorp distribution, then Labcorp acquisition — matches that consolidation pattern.

Foundation Medicine (Roche) direct

Leading comprehensive genomic profiling incumbent.
Guardant / liquid biopsy platforms adjacent

Blood-based profiling; different sample type.
Other CAP/CLIA oncology NGS labs direct

Hospital and commercial labs offering tumor panels.

Notable stories

Labcorp and OmniSeq launched INSIGHT together in June 2021, weeks before Labcorp announced the July 29, 2021 acquisition (Labcorp Oncology / PR Newswire).

Industries

Biotech & Life Sciences Healthtech

FAQs about OmniSeq

Practical answers founders, operators, and investors typically search for.

Molecular diagnostics for solid tumors — genomic and immune profiling assays, including OmniSeq INSIGHT NGS testing.

Buffalo, NY (Roswell Park medical campus area).

July 29, 2021 — acquired by Labcorp.

Commercial innovation of Roswell Park Comprehensive Cancer Center's Center of Personalized Medicine (founded 2015).

Public summaries have named Labcorp (strategic), Baseline Ventures, Roswell Park, and Hitachi High-Tech among historical backers. We keep investors[] empty — no matching VCT fund ids for that set.

No — integrated into Labcorp Oncology after the 2021 acquisition.

A tissue-based comprehensive genomic and immune profiling NGS test for solid tumors, distributed with Labcorp before and after the acquisition.

HQ was Buffalo, NY through acquisition; profile kept for Buffalo startup coverage and exit history.

stage: acquired; status: acquired.

No standalone site is listed here — Labcorp Oncology hosts OmniSeq legacy product information.

OmniSeq startup funding profile

Stage

Status

Coverage